Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Rosonabant

CB1 antagonist of the rimonabant series, studied in clinical settings according to a 2009 review; little public data.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₁H₂₁Cl₃N₄O

CAS 861151-12-4

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
451.80 g/mol

Updated on

In plain terms

Rosonabant is an experimental molecule designed, like rimonabant, to block the CB1 receptor. A 2009 review lists it among the drug candidates studied in humans. Neither published results nor a marketing authorisation were found.

Receptors and activity

Target network

CB1Antagonistclassified among the CB1 antagonists/inverse agonists (review by Janero and Makriyannis 2009); no affinity value found
  • Blocks or inhibits

The lower the cited value, the closer the target sits to Rosonabant: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Rosonabant.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Antagonistno measured value cited

    classified among the CB1 antagonists/inverse agonists (review by Janero and Makriyannis 2009); no affinity value found

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Rosonabant (code E-6776) is an antagonist of the CB1 receptor, of the pyrazoline carboxamide family. A 2009 review lists it among the agents following rimonabant that have been studied in the clinic, alongside taranabant, otenabant, surinabant, SLV-319, AVE1625 and V24343 (Janero and Makriyannis 2009). The context of the class is known: rimonabant, authorised in the European Union in June 2006, had its authorisation recommended for suspension by the CHMP on 23 October 2008 (risk of psychiatric disorders approximately doubled compared with placebo, according to the EMA), and the 2009 review reports the suspension of the development programmes of rimonabant, taranabant and otenabant. The fate of rosonabant's development, its pharmacological data and its clinical results are not documented in the sources consulted: the entry deliberately remains sparse.

History

Source
Entirely synthetic compound with no known natural occurrence. It was studied in clinical settings as an antagonist or inverse agonist of the CB1 receptor (Janero and Makriyannis 2009); no marketing authorisation was found.

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It is a pyrazoline (4,5-dihydropyrazole) carboxamide, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-3,4-dihydropyrazole-5-carboxamide (name read on PubChem, CID 11316914).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Rosonabant (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-piperidin-1-yl-3,4-dihydropyrazole-5-carboxamide
Other names
E-6776 · E 6776

Identifiers

Formula
C₂₁H₂₁Cl₃N₄O
CAS
861151-12-4
InChIKey
WMMMJGKFKKBRQR-UHFFFAOYSA-N
SMILES
C1CCN(CC1)NC(=O)C2=NN(C(C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.